AMD

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.

A study reveals that ophthalmic artery angioplasty improves vision and functionality in patients with late-stage age-related macular degeneration.

The acquisition includes the noninvasive Valeda PBM device for the treatment of early and intermediate dry age-related macular degeneration.

Ashvattha Therapeutics reveals phase 2 results for migaldendranib, showing significant vision improvements and reduced injection needs in retinal disease patients.

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company after the COAST trial failed to meet its primary end point.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes.

The role of anesthetics in streamlining efficiency and elevating patient care.

Patients weigh in on the value of provider communication.

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.